G. Monfette

发表

New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens

F. Labrie, J. Raynaud, A. Bélanger, 1983, The Prostate.

Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men.

F. Labrie, A. Bélanger, A. Dupont, 1989, Journal of steroid biochemistry.

Combined Therapy with an LHRH Agonist and an Antiandrogen in Prostatic Carcinoma

F. Labrie, J. Raynaud, A. Bélanger, 1984 .

Medical Castration with LHRH Agonists and the Need for Combined Treatment with an Antiandrogen in Prostate Cancer

C. Labrie, A. Vallières, F. Labrie, 1984 .

Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival.

F. Labrie, A. Bélanger, A. Dupont, 1985, Journal of steroid biochemistry.

Combination therapy in stage C and D prostatic cancer: rationale and five-year clinical experience

J. Simard, C. Labrie, F. Labrie, 2004, Cancer and Metastasis Reviews.

Combination therapy with flutamide and castration (orchiectomy or LH-RH agonist) in untreated patients with advanced prostate cancer.

J. Goméz, F. Labrie, Y. Lacourciére, 1992, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Combination therapy with flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experience

J. Goméz, F. Labrie, A. Dupont, 1990, The Journal of Steroid Biochemistry and Molecular Biology.

Maximal Androgen Blockage in Prostate Cancer: Today’s Therapy of Choice and 5-Year Clinical Experience

F. Labrie, Y. Lacourciére, A. Dupont, 1990 .

Combination Therapy with the Antiandrogen Flutamide and the LHRH Agonist [D-Trp 6 , des-Gly-NH 2 10 ]LHRH Ethylamide in Prostate Cancer: Rationale and 5-Year Clinical Experience

J. Simard, B. Marchetti, C. Labrie, 1988 .

Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice.

F. Labrie, Y. Lacourciére, A. Bélanger, 1988, Journal of steroid biochemistry.

Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients.

F. Labrie, Y. Lacourciére, A. Bélanger, 1987, Journal of steroid biochemistry.

Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.

F. Labrie, Y. Lacourciére, A. Bélanger, 1986, Journal of steroid biochemistry.

Treatment of prostate cancer with gonadotropin-releasing hormone agonists.

F. Labrie, Y. Lacourciére, R. St-Arnaud, 1986, Endocrine reviews.

COMBINED TREATMENT WITH FLUTAMIDE AND SURGICAL OR MEDICAL (LHRH AGONIST) CASTRATION IN METASTATIC PROSTATIC CANCER

P. Poyet, F. Labrie, Y. Lacourciére, 1986, The Lancet.

COMBINED TREATMENT WITH LHRH AGONIST AND PURE ANTIANDROGEN IN ADVANCED CARCINOMA OF PROSTATE

F. Labrie, A. Bélanger, A. Dupont, 1984, The Lancet.

Effect of Combination Endocrine Therapy (LHRH Agonist and Flutamide) on Normal Prostate and Prostatic Adenocarcinoma: A Histopathologic and Immunohistochemical Study

J. Srigley, F. Labrie, A. Dupont, 1991, The American journal of surgical pathology.

Combination therapy with castration and flutamide: today's treatment of choice for prostate cancer.

F. Labrie, Y. Lacourciére, A. Bélanger, 1989, Journal of steroid biochemistry.

Benefits of combination therapy with flutamide in patients relapsing after castration.

F. Labrie, Y. Lacourciére, A. Dupont, 1988, British journal of urology.

Combined Treatment with an LHRH Agonist and the Antiandrogen Flutamide in Prostate Cancer

F. Labrie, Y. Lacourciére, A. Bélanger, 1986 .

New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen.

F. Labrie, J. Raynaud, A. Bélanger, 1983, Journal of steroid biochemistry.

New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.

F. Labrie, Y. Lacourciére, J. Raynaud, 1982, Clinical and investigative medicine. Medecine clinique et experimentale.

COMBINATION THERAPY IN PROSTATE CANCER

F. Labrie, A. Dupont, G. Monfette, 1986, The Lancet.

Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.

F. Labrie, Y. Lacourciére, A. Bélanger, 1988, Progress in clinical and biological research.

Transrectal ultrasound evaluation of local prostate cancer in patients treated with LHRH agonist and in combination with flutamide.

F. Labrie, A. Dupont, G. Monfette, 1992, Urology.

Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer.

F. Labrie, A. Bélanger, A Bélanger, 1984, Proceedings of the National Academy of Sciences of the United States of America.

Combination therapy in prostate cancer.

F. Labrie, A. Dupont, G. Monfette, 1986, British medical journal.

Multiple Advantages Before and After Radical Prostatectomy with Combined Endocrine Therapy

F. Labrie, A. Dupont, G. Monfette, 1991 .

Important prognostic value of standardized objective criteria of response in stage D2 prostatic carcinoma.

F. Labrie, Y. Lacourciére, R. Lachance, 1988, European journal of cancer & clinical oncology.